Explainable AI in Regulatory Compliance for Pharmaceutical Manufacturing

Abstract

AI aids many industries, including health. Meeting regulatory bodies' strict drug research and manufacturing criteria is essential. Manual compliance and post-production audits may hurt complex industrial operations. Companies may follow GMP, quality control, and other requirements using Explainable AI. This study tests XAI models for pharmaceutical manufacturing compliance. This method's pros and cons are examined. 

Unlike "black-box" AI, XAI explains AI decisions. The FDA and EMA require confirmation of patient safety, therapeutic effectiveness, and manufacturing quality for all pharmaceutical activities. XAI compliance is essential for pharmaceutical companies. It enhances automated processes and provides regulators with AI insights. 

This study addresses XAI pharmaceutical production regulation. XAI models may help firms improve by highlighting everyday operational issues. These proactive quality assurance methods vary from post-conformity checks. By explaining AI system conclusions, XAI bridges automated processes' complexity to regulators' human judgement, improving compliance. 

XAI checks pharmaceutical production quality, batch release, and record keeping. AI models can monitor drug manufacturing humidity and temperature. The models detect hazards and explain how departures from ideal circumstances impact product quality. Increases GMP compliance. XAI can explain deviation-related changes to help producers track deviations. This openness lets regulators readily verify that all remedial efforts meet industry standards, decreasing penalty risk. 

regulatory compliance paperwork is automated by XAI. This key drug-making phase is managed. AI-powered automated systems can produce complete, up-to-date records inspectors can comprehend. This prevents human error and assures manufacturing data correctness. For crucial paper generation and revisions, XAI may explain each documentation stage to regulatory bodies. 

But XAI has flaws. Complex AI models frighten me. XAI explains, yet model options might be unclear, particularly in complex fields like drug development. Complex explanations may inspire distrust, especially when humans confirm AI thinking. Adding XAI to drug manufacture may cost time and money. AI will simplify compliance checks, therefore regulators must audit and inspect differently. These may involve integrating AI-driven models and processes to legislation and explaining AI decisions. 

Other privacy and security issues must be addressed. Clinical trials and patient records are sensitive pharmaceutical development data. Explainable AI systems steal and abuse data. Protecting AI and sensitive data is essential. AI assessments are morally problematic even while following criteria. XAI can clarify options, but streamlining medicine manufacture may violate regulations. 

Despite these obstacles, XAI may enhance rule-following. By making decision-making visible, comprehensible, and auditable, XAI models may help pharmaceutical companies achieve greater regulatory criteria and perform better. Development of regulatory-adaptive AI systems is simplified by XAI. This changes compliance as pharmaceutical production improves. 

This article covers medication XAI application research. XAI and advanced machine learning algorithms automate and improve regulatory compliance. Researchers must employ blockchain to ensure pharmaceutical manufacturing transparency and responsibility. Pharmaceutical businesses, regulators, and AI developers must cooperate to find XAI models.